Elevation Oncology (ELEV) Competitors $0.28 -0.01 (-2.41%) Closing price 04:00 PM EasternExtended Trading$0.29 +0.00 (+1.73%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELEV vs. TELO, RENB, VIRI, EDIT, ADAP, SLN, SGMT, COYA, NKTX, and DERMShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Telomir Pharmaceuticals (TELO), Renovaro (RENB), Virios Therapeutics (VIRI), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Silence Therapeutics (SLN), Sagimet Biosciences (SGMT), Coya Therapeutics (COYA), Nkarta (NKTX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Elevation Oncology vs. Telomir Pharmaceuticals Renovaro Virios Therapeutics Editas Medicine Adaptimmune Therapeutics Silence Therapeutics Sagimet Biosciences Coya Therapeutics Nkarta Journey Medical Telomir Pharmaceuticals (NASDAQ:TELO) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment. Do insiders and institutionals have more ownership in TELO or ELEV? 83.7% of Elevation Oncology shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is TELO or ELEV more profitable? Elevation Oncology's return on equity of -59.73% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -1,170.58% -832.67% Elevation Oncology N/A -59.73%-40.05% Does the MarketBeat Community favor TELO or ELEV? Elevation Oncology received 37 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Telomir Pharmaceuticals an outperform vote while only 67.24% of users gave Elevation Oncology an outperform vote. CompanyUnderperformOutperformTelomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo VotesElevation OncologyOutperform Votes3967.24% Underperform Votes1932.76% Do analysts recommend TELO or ELEV? Telomir Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 243.96%. Elevation Oncology has a consensus price target of $3.39, suggesting a potential upside of 1,092.15%. Given Elevation Oncology's higher probable upside, analysts plainly believe Elevation Oncology is more favorable than Telomir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Elevation Oncology 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger earnings & valuation, TELO or ELEV? Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.58-7.52Elevation OncologyN/AN/A-$45.70M-$0.81-0.35 Does the media refer more to TELO or ELEV? In the previous week, Elevation Oncology had 27 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 31 mentions for Elevation Oncology and 4 mentions for Telomir Pharmaceuticals. Elevation Oncology's average media sentiment score of -0.47 beat Telomir Pharmaceuticals' score of -0.58 indicating that Elevation Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Negative Elevation Oncology 0 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryElevation Oncology beats Telomir Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Remove Ads Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.82M$3.04B$5.73B$8.32BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-0.3529.9824.6719.35Price / SalesN/A450.01391.7596.59Price / CashN/A168.6838.1634.64Price / Book0.224.257.154.48Net Income-$45.70M-$71.72M$3.20B$247.04M7 Day Performance-41.02%-1.02%2.16%3.44%1 Month Performance-47.00%-8.56%6.67%-2.48%1 Year Performance-93.80%-21.89%15.52%4.92% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology2.4511 of 5 stars$0.28-2.4%$3.39+1,095.9%-93.6%$16.76MN/A-0.3540Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeTELOTelomir Pharmaceuticals1.8068 of 5 stars$4.17-9.0%$15.00+259.7%-30.2%$124.11MN/A-7.191RENBRenovaro0.9429 of 5 stars$0.77-4.6%N/A-77.8%$121.88MN/A-0.8320Positive NewsGap UpVIRIVirios Therapeutics0.2495 of 5 stars$6.12-20.8%$3.00-51.0%+1,283.9%$117.86MN/A-22.675Gap UpEDITEditas Medicine4.2683 of 5 stars$1.41-3.4%$6.83+384.6%-81.4%$117.00M$32.31M-0.55230Positive NewsGap DownADAPAdaptimmune Therapeutics2.1859 of 5 stars$0.46+1.4%$2.79+510.4%-80.8%$116.86M$175.04M-2.08490Earnings ReportNews CoverageSLNSilence Therapeutics2.7723 of 5 stars$3.90-0.3%$40.67+942.7%-84.1%$116.73M$43.26M-2.48100Positive NewsGap DownSGMTSagimet Biosciences2.4786 of 5 stars$3.78+1.1%$23.00+508.5%-8.4%$115.95M$2M-2.648COYACoya Therapeutics2.1971 of 5 stars$6.85+5.5%$16.25+137.2%-31.6%$114.44M$9.55M-10.546Earnings ReportNKTXNkarta2.2453 of 5 stars$1.62-2.4%$15.00+825.9%-82.6%$114.32MN/A-0.86140DERMJourney Medical2.6014 of 5 stars$5.31+1.1%$9.67+82.0%+98.2%$110.93M$57.77M-5.6590 Remove Ads Related Companies and Tools Related Companies TELO Alternatives RENB Alternatives VIRI Alternatives EDIT Alternatives ADAP Alternatives SLN Alternatives SGMT Alternatives COYA Alternatives NKTX Alternatives DERM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELEV) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
